How does BMY's 2024 EPS compare to peers?

Bristol-Myers Squibb's (BMY) 2024 EPS of -$4.41 is significantly lower than most of its peers in the Pharmaceuticals industry, with only a few exceptions: |code|Ticker|Name|Date|Diluted EPS|market_code| |---|---|---|---|---|---| |SISI|SISI.O|Shineco|20240331|40.75|186| |RGLS|RGLS.O|Regulus Therapeutics|20240331|-0.29|186| |TTNP|TTNP.O|Titan Pharmaceuticals|20240331|-1.24|186| |NCNA|NCNA.O|Nucana|20240331|-0.164281|186| |QLGN|QLGN.O|Qualigen|20240331|-0.35|186| |BMY|BMY.N|Bristol-Myers Squibb|20240331|-5.89|169| |MIST|MIST.O|Milestone|20240331|-0.21|185| |ABVC|ABVC.O|ABVC BioPharma|20240331|-0.4|186| |QNTM|QNTM.O|Quantum BioPharma|20240331|-0.05|186| |IBRX|IBRX.O|ImmunityBio|20240331|-0.2|185| This indicates that BMY's financial performance in 2024 was notably weaker than that of many of its industry peers.